Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01709110 · ClinicalTrials.gov registry record · Phase 4
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,366
- Enrollment target
NCT01709110: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT01709110 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,366 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (164% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01709110, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,366 participants
- Enrollment target
Study Summary
The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.
Primary Outcome
The incidence of new vertebral fractures was assessed by quantitative vertebral morphometry measurements (QM) with qualitative visual semiquantitative grading (SQ) confirmation. A new vertebral fracture was diagnosed in a vertebra that was non-fractured at the baseline radiological examination. It was defined as a loss of vertebral body height of at least 20% and 4 mm from the baseline radiograph by vertebral QM, based upon placement of six points by a trained, central reader. Any fractures ide
Interventions
- DRUG Placebo
- DRUG Risedronate
- DRUG Teriparatide
- DRUG Calcium
- DRUG Vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,366 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-07 |
| Phase | Phase 4 |
What the finished NCT01709110 record still lists
NCT01709110 is an interventional study that assigns participants to a tested intervention. Its 1,366 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (164% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01709110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01709110 about?
NCT01709110 is a clinical study titled "VERtebral Fracture Treatment Comparisons in Osteoporotic Women". The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.
What is the current status of trial NCT01709110?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,366 participants. The study started on 2012-10. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01709110?
The interventions under investigation include: Placebo (DRUG), Risedronate (DRUG), Teriparatide (DRUG), Calcium (DRUG), Vitamin D (DRUG).
Who is sponsoring clinical trial NCT01709110?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01709110's enrollment target sits among peer trials
1,366 55th of 2000 higher than 1,946 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia